Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! It's time to kick off another busy day of trading with the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
Exposures Product Safety
21 Stocks Moving in Thursday's Pre-Market Session
Gainers Pear Therapeutics, Inc. (NASDAQ: PEAR) rose 64% to $15.20 in pre-market trading after climbing around 16% on Wednesday. Ensysce Biosciences, Inc. (NASDAQ: ENSC) rose 32.2... 
Via Benzinga
REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
From Reata Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
From Reata Pharmaceuticals, Inc.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
60 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore... 
Via Benzinga
FDA Raises Concerns On Reata's Kidney Disease Drug Data; Shares Plunge
Reata Pharmaceuticals Inc (NASDAQ: RETA) shares are trading lower during the market trading session after the FDA released briefing documents ahead of the Advisory... 
Via Benzinga
Exposures Product Safety
Reata Pharma Stock Dives 40% As FDA Reviewers Waffle On Kidney Disease Drug
FDA experts are set to debate the drug's merits and risks on Wednesday. 
Via Investor's Business Daily
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Adicet Bio (NASDAQ:ACET) shares i... 
Via Benzinga
36 Stocks Moving In Monday's Mid-Day Session
Gainers Del Taco Restaurants, Inc. (NASDAQ: TACO) shares jumped 64.6% to $12.40. Jack In The Box Inc (NASDAQ: JACK) agreed to acquire Del Taco Restaurants for $12.51 per share... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings
Following the market opening Monday, the Dow traded up 1.35% to 35,048.01 while the NASDAQ fell 0.17% to 15,059.43. The S&P also rose, gaining 0.59% to 4,565.21. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Pharmaceuticals, inc (RETA) Q3 2021 Earnings Call Transcript
RETA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Reata Pharmaceuticals's Return On Capital Employed Overview
According to Benzinga Pro data, during Q3, Reata Pharmaceuticals (NASDAQ:RETA) posted sales of $7.39 million. Earnings were up 3.38%, but Reata Pharmaceuticals still reported an... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Reata Pharmaceuticals: Q3 Earnings Insights
Reata Pharmaceuticals (NASDAQ:RETA) reported its Q3 earnings results on Monday, November 8, 2021 at 08:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
A Preview Of Reata Pharmaceuticals's Earnings
Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Reata Pharmaceuticals, Inc. to Report Third Quarter 2021 Financial Results and to Provide an Update on Development Programs on November 8, 2021
From Reata Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
Reata Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Pharmaceuticals Announces Presentations at the American Society of Nephrology Kidney Week 2021
From Reata Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.